Dr Tim Corn was appointed to the Board in June 2012 and has just been appointed Chairman.
He serves as Chief Medical Officer of both Izana Bioscience and Akasa Bioscience, and Trustee of Nerve Tumours UK.
He was formerly Chief Medical Officer at EUSA Pharma International, a division of Jazz Pharmaceuticals, at EUSA Pharma Inc and at Zeneus Pharma, as well as Non-executive Director at Circassia Pharmaceuticals plc, Neurocentrx Pharma Ltd and HRA Pharma.
He has held senior medical, clinical and regulatory positions in both big and small pharma as well as in the UK regulatory agency and has played a key role in more than 20 regulatory approvals in the USA and Europe for products mainly in the fields of neurology and oncology.
Dr. Corn qualified in medicine at King’s College Hospital, London after gaining a Master’s degree in biochemistry from Imperial College. He became consultant and senior lecturer in neuropsychiatry at the Institute of Psychiatry, London and is author of more than forty scientific publications.
He is a Fellow of both the Faculty of Pharmaceutical Medicine in 1996 and the Royal College of Psychiatrists
Olav Hellebø was appointed to the Board in September 2014.
Prior to ReNeuron, he held the role of CEO at Clavis Pharma ASA, a Norwegian, oncology-focused, listed biotechnology company. He joined Clavis from UCB where he built the global organisation responsible for the successful registration and launch of the anti-TNF Cimzia®. Mr Hellebø was COO of Novartis UK and prior to that held a series of senior roles at Schering Plough, including US marketing director for Claritin and head of the Biotech Oncology Business Unit in the USA.
Olav has an MBA from the IESE Business School in Spain and a Bachelor of Business Administration from Hofstra University, USA.
Michael Hunt joined ReNeuron in 2001. Between 2005 and 2014 he served as its CEO, leading the business through its early development to its current position as one of the global, clinical-stage leaders in the regenerative medicine field. He was appointed Chief Financial Officer in 2014.
He sits on the Board and Executive Committee of the US-based Alliance for Regenerative Medicine (ARM) and is a founding member and co-chair of ARM’s European Section. He sits on the UK BioIndustry Association’s Cell & Gene Therapy Advisory Committee and its Finance and Tax Advisory Committee and is a member of the Cell & Gene Therapy Catapult’s Advisory Panel.
Prior to ReNeuron, he spent six years at Biocompatibles International plc (sold to BTG plc) where he held a number of senior financial and general management positions. His early industrial career was spent at Bunzl plc.
He read economics at University College London and qualified as a chartered accountant with Ernst & Young
Professor Sir Chris Evans OBE was appointed to the Board in August 2013.
He was the founder of Chiroscience, Celsis, Biovex, Merlin Biosciences, Vectura, Piramed, Excalibur Group, Arthurian Life Sciences, Arix Bioscience plc and Proton Partners. He is also currently Founder and Chairman of Ellipses Pharma, a new cancer medicines company.
He has built over 50 medical companies from scratch, many from his own ideas and inventions, and floated 20 new medical businesses on stock markets in six different countries. He has created companies worth over $7 billion employing over 4,000 scientists, built hundreds of complex medical laboratories and facilities around the world and positively impacted many millions of lives with his work. He has also raised $2 billion for cancer research projects. He has received numerous prestigious awards and medals for his work and was knighted in the year 2000.
Mark Evans was appointed to the Board in September 2020.
Mark, a chemistry graduate from the University of Bristol, began his career as a graduate trainee at Morgan Grenfell, a British merchant bank. He then worked in emerging markets at ING Bank and Montpelier Asset Management before joining THS Partners in 1998 to manage global equity portfolios. He followed a number of areas at THS, including property, fixed interest and healthcare. He also chaired the risk management committee and was the finance partner. THS was sold to GAM in 2016.
Mark and two colleagues started a new firm, Partners Investment Company LLP, to focus on small and midcap European equities. Mark is also a partner of Albemarle Life Sciences LLP, a small specialist healthcare investment partnership.
Dr Mike Owen was appointed to the Board in December 2015.
He currently serves as a director of Zealand Pharma, Ossianix Inc. Ossianix UK Ltd, Avacta plc, GammaDelta Therapeutics Ltd and is a member of the scientific advisory board at Avacta.
His career in biotech, the pharmaceutical industry and academia spans almost 40 years. He was formerly Senior vice president for biopharmaceuticals research at GlaxoSmithKline and was also a founder and chief scientific officer of Kymab Ltd, an antibody based biotech company. He has previously served as a director for BliNK Biomedical SAS. For many years held a research position at the Imperial Cancer Research Fund (now CR-UK) and he has previously served on the scientific advisory board of the CRT Pioneer Fund LP.
He is also a member of the European Molecular Biology Organisation and a Fellow of the Academy of Medical Sciences.